Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462030 · ClinicalTrials.gov registry record · Phase 2
Baked Milk Oral Immunotherapy for Cow's Milk Allergy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT03462030: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03462030 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03462030, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether baked milk oral immunotherapy is safe in the treatment of cow's milk allergy.
Primary Outcome
Adverse events will be recorded per CTCAE version 4.0. Events per dose on baked milk oral immunotherapy will be compared to adverse events per dose on placebo. Data will be collected over the first year of treatment. Analysis of cumulative adverse reactions per dose of oral immunotherapy or placebo will be performed at the end of year 1.
Interventions
- DRUG Baked non-fat cow's milk powder
- DRUG Placebo: Tapioca Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2024-02-19 |
| Phase | Phase 2 |
What the finished NCT03462030 record still lists
NCT03462030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Baked non-fat cow's milk powder is the first listed.
NCT03462030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03462030 about?
NCT03462030 is a clinical study titled "Baked Milk Oral Immunotherapy for Cow's Milk Allergy". The purpose of this study is to determine whether baked milk oral immunotherapy is safe in the treatment of cow's milk allergy.
What is the current status of trial NCT03462030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2018-03-15. Estimated completion is 2024-02-19.
What interventions are being tested in trial NCT03462030?
The interventions under investigation include: Baked non-fat cow's milk powder (DRUG), Placebo: Tapioca Powder (DRUG).
Who is sponsoring clinical trial NCT03462030?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03462030's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI